Catalyst
Slingshot members are tracking this event:
Following Phase I/II trial results, Immunomedics (IMMU) to file sacituzumab govitecan for accelerated approval in triple-negative breast cancer in mid-2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMU | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 08, 2018
Occurred Source:
https://immunomedics.com/2018/immunomedics-announces-second-quarter-fiscal-2018-results-provides-corporate-update/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Sacituzumab Govitecan, Accelarated Approval, Triple-negative Breast Cancer, Phase 1/2
